Lead Cancer Drug PH-762 Shows Favorable Phase 1b Data; $23.7M Financing Extends Cash Runway to 2027
summarizeSummary
Phio Pharmaceuticals reported its 2025 year-end financial results and provided a significant business update. The company announced favorable safety, tolerability, and pathology data from the completed Phase 1b dose escalation trial for its lead clinical candidate, PH-762, targeting various carcinomas. Crucially, Phio strengthened its balance sheet with $23.7 million in net proceeds from 2025 financings and warrant exercises, extending its cash runway into the first half of 2027. For a clinical-stage biopharmaceutical company, positive early-stage clinical data for a lead asset is a significant de-risking event, especially with an FDA submission for next steps targeted for Q2 2026. The substantial capital raise and extended cash runway are critical for funding ongoing clinical development and operations, providing essential financial stability. Investors will now focus on the upcoming FDA submission in Q2 2026 for guidance on the next clinical study design for PH-762, which will be a key catalyst.
At the time of this announcement, PHIO was trading at $1.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.6M. The 52-week trading range was $0.81 to $4.19. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: TMX Newsfile.